CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for NUCRYST Pharmaceuticals Corp. (USA) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

NUCRYST Pharmaceuticals Corp. (USA)
50 Audubon Road, Suite B
Phone: (781) 224-1444p:781 224-1444 Wakefield, MA  01880  United States Ticker: NCST NCST

This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company

Business Summary
NUCRYST Pharmaceuticals Corp. (NUCRYST) develops, manufactures and commercializes medical products that fight infection and inflammation. The Company’s technology converts silver’s microcrystalline structure into an atomically disordered nanocrystalline coating that enhances silver’s natural antimicrobial properties. In addition, its nanocrystalline silver structures have exhibited potent anti-inflammatory properties in preclinical studies. NUCRYST produces nanocrystalline silver as a coating for wound dressing products under the trademark SILCRYST and as a powder, for use in medical devices and as an active pharmaceutical ingredient (API). The Company is a majority owned subsidiary of The Westaim Corporation (Westaim). In December 2009, the Company sold all of the assets of the Company. In February 2010, the Company completed the amalgamation of Nucryst with 1499642 Alberta Ltd., a wholly owned subsidiary of the Westaim Corporation.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/200912/31/2008YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Vice President - Operations David C.McDowell 53 7/1/2005 7/1/2005

Business Names
Business Name
NCS
NCST
NUCRYST Pharmaceuticals Corp.
NUCRYST Pharmaceuticals Corp. (USA)

General Information
Number of Employees: 106 (As of 12/31/2008)
Outstanding Shares: 18,325,365 (As of 11/25/2009)
Shareholders: 17
Stock Exchange: NASD
Fax Number: (781) 246-6002


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023